• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Progressive Rash and Arthralgias in a Teenage Male

News
Poll

PT Video: A short course of steroids was ineffective. He returns to ED c/o worsening joint and abdominal pain. Can you Dx?

A 16 y/o male presents with 9 days palpable, purpuric, non-pruritic rash that began on legs and spread quickly upwards; also c/o polyarticular arthritis, abdominal pain. Mild improvement after short course of steroids, finished 2 days ago. Joint/abdominal pain now worse. PMH, noncontributory; no sick contacts. What else do you need to know?

 

What is your initial impression?

A. Henoch-Schönlein purpura
B. Epstein-Barr virus infection
C. Juvenile idiopathic arthritis (Still’s disease)
D. Systemic lupus erythromatosis (SLE)
E. Thrombocytopenic disease (ITP, TTP, DIC)
F. Rickettsial disease
G. Purpura fulminans
Related Content
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

Patient Care Staff
January 15th 2025
Article

Early proof-of-concept phase 1a data from the trial is anticipated in the third quarter of 2025.

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment / image credit ©MichaelVI/stock.adobe.com

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

Grace Halsey
January 13th 2025
Article

Nektar Therapeutics announced the milestone in its clinical program to evaluate the IL-2 receptor agonist, a potential first-in-class treatment for the chronic condition.

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025
Article

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose / image credit: ©New Africa/AdobeStock

FDA OKs Tapinarof Cream, 1% for Atopic Dermatitis In Patients Aged 2 Years and Older: Daily Dose

Sydney Jennings
January 8th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Greenlights New Treatment for Moderate-to-Severe Atopic Dermatitis: Daily Dose

Sydney Jennings
January 6th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA Accepts sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years / image credit DOCS Dermatology Rocco Serrao, MD

FDA Receives sNDA for Roflumilast Cream 0.05% to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Grace Halsey
December 16th 2024
Article

Arcutis Biotherapeutics announced submission of the sNDA today, citing the the supporting positive data from the phase 3 INTEGUMENT-PED and INTEGUMENT-OLE trials.

© 2025 MJH Life Sciences

All rights reserved.